Wilma M Tamraz

20110136847, Jun 9, 2011

Sep 17, 2010

12/885345

Tai Wah Chan - Palo Alto CA, US
Wilma Tamraz - San Jose CA, US
Min Lee - Saratoga CA, US

A61K 31/46
A61K 31/4535
A61K 31/445
A61P 29/00

514282, 514326, 514329

The present invention provides opioid formulations suitable for long-term delivery to a subject. The formulation of the invention comprises an opioid or opioid derivative (e.g., morphine, hydromorphone, fentanyl or a fentanyl congener), and an aqueous solvent comprising a low molecular weight carboxylic acid (e.g., C, C). The invention thus provides for formulations comprising morphine, hydromorphone, fentanyl or fentanyl congeners in concentrations significantly in excess of conventional aqueous formulations, e.g., on the order about 2-fold to about 10,000-fold greater than conventional formulations, e.g., currently commercially available formulations.

20040102476, May 27, 2004

Nov 25, 2002

10/305252

Tai Chan - Palo Alto CA, US
Wilma Tamraz - San Jose CA, US
Min Lee - Saratoga CA, US

A61K031/445
A61K031/19

514/317000, 514/557000

The present invention provides opioid formulations suitable for long-term delivery to a subject. The formulation of the invention comprises an opioid or opioid derivative (e.g., morphine, hydromorphone, fentanyl or a fentanyl congener), and an aqueous solvent comprising a low molecular weight carboxylic acid (e.g., C, C). The invention thus provides for formulations comprising morphine, hydromorphone, fentanyl or fentanyl congeners in concentrations significantly in excess of conventional aqueous formulations, e.g., on the order about 2-fold to about 10,000-fold greater than conventional formulations, e.g., currently commercially available formulations.

20220280646, Sep 8, 2022

Feb 14, 2022

17/671447

- Cupertino CA, US
Wilma TAMRAZ - San Jose CA, US
John J. LEONARD - Morgan Hill CA, US
John W. GIBSON - Springville AL, US
Keith E. BRANHAM - Pelham AL, US
Stefania SJOBECK - Glumsloev, SE
Brooks Boyd - Emeryville CA, US
Christopher M. RUBINO - Latham NY, US

DURECT CORPORATION - Cupertino CA

A61K 47/22
A61K 9/00
A61K 31/519
A61K 47/20
A61K 47/26
A61M 5/20
A61M 5/24
A61M 5/30
A61M 5/315

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25 C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

20210015924, Jan 21, 2021

Jun 1, 2020

16/889115

- Cupertino CA, US
Wilma TAMRAZ - San Jose CA, US
John J. LEONARD - Morgan Hil CA, US
John W. GIBSON - Springville AL, US
Keith E. BRANHAM - Pelham AL, US
Stefania SJOBECK - Glumsloev, SE
Brooks Boyd - Emeryville CA, US
Christopher M. RUBINO - Latham NY, US

DURECT CORPORATION - Cupertino CA

A61K 47/22
A61K 9/00
A61K 31/519
A61K 47/20
A61K 47/26
A61M 5/20
A61M 5/24
A61M 5/30
A61M 5/315

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic- acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25 C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

20200085829, Mar 19, 2020

Aug 19, 2019

16/544276

- Cupertino CA, US
Wilma TAMRAZ - San Jose CA, US
John J. LEONARD - Morgan Hil CA, US
John W. GIBSON - Springville AL, US
Keith E. BRANHAM - Pelham AL, US
Stefania SJOBECK - Glumsloev, SE
Brooks BOYD - Emeryville CA, US
Christopher M. RUBINO - Latham NY, US

DURECT CORPORATION - Cupertino CA

A61K 31/519
A61M 5/30
A61K 9/00
A61K 47/10
A61K 47/20
A61K 47/22
A61K 47/26
A61K 47/34
A61K 9/10
A61K 9/16
A61K 9/08
A61K 9/19
A61K 41/00
C08G 63/08
C08G 63/91

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.

20190374554, Dec 12, 2019

Aug 1, 2017

16/320400

- Richmond VA, US
- Cupertino CA, US
James E. Brown - Los Gatos CA, US
Felix Theeuwes - Los Altos Hills CA, US
Mee Jean Kim - San Francisco CA, US
Andrew R. Miksztal - Palo Alto CA, US
Hongwei Wu - Cupertino CA, US
Min L. Lee - Saratoga CA, US
Huey-Ching Su - San Jose CA, US
Wilma Tamraz - San Jose CA, US

A61K 31/575
A61K 47/12
A61K 47/10
A61K 47/14
A61K 9/06
A61P 17/06

Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.

20190269695, Sep 5, 2019

Aug 1, 2017

16/320079

- Richmond VA, US
- Cupertino CA, US
Yanxia Ning - Richmond VA, US
Jin Koung Kim - Richmond VA, US
WeiQi Lin - Emerald Hills CA, US
Mee Jean Kim - San Francisco CA, US
Andrew R. Miksztal - Palo Alto CA, US
Hongwei Wu - Cupertino CA, US
Min L. Lee - Saratoga CA, US
Wilma Tamraz - San Jose CA, US

A61K 31/565
A61P 1/16
A61P 17/06
A61P 3/06
A61P 31/04
A61K 31/724
A61K 47/10

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

20190255179, Aug 22, 2019

Jan 17, 2019

16/250614

- Cupertino CA, US
Wilma TAMRAZ - San Jose CA, US
John J. LEONARD - Morgan Hil CA, US
John W. GIBSON - Springville AL, US
Keith E. BRANHAM - Pelham AL, US
Stefania SJOBECK - Glumsloev, SE
Brooks Boyd - Emeryville CA, US
Christopher M. RUBINO - Latham NY, US

DURECT CORPORATION - Cupertino CA

A61K 47/22
A61M 5/20
A61K 47/20
A61K 47/26
A61K 9/00
A61M 5/24
A61M 5/30
A61M 5/315
A61K 31/519

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25 C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.